|Bid||33.35 x 600|
|Ask||33.42 x 200|
|Day's Range||33.17 - 33.44|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||28.05|
|Dividend & Yield||1.28 (3.82%)|
|1y Target Est||N/A|
Pfizer (PFE) is extensively conducting clinical trials for the label expansion of Ibrance.
In 2016, Pfizer’s (PFE) Ibrance reported revenues of ~$2.1 billion, compared with $723 million in 2015.
The days of high-priced knockoffs of biologic drugs are ending quickly.